In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

2019 ESC Clinical Practice Guidelines - what’s new?

ESC Congress News 2019 - Paris, France

With five new ESC Clinical Practice Guidelines being presented at ESC Congress 2019 and simultaneously published in the European Heart Journal, it’s been a very busy time for the ESC’s Committee for Practice Guidelines (CPG) and the expert Task Forces.

Check out the Scientific Programme for all ESC Guidelines sessions >

Access the new 2019 Guidelines >

Diabetes and the Heart
Coronary Artery Disease (Chronic)
Pulmonary Embolism
Lipids
Supraventricular Tachycardia (non-AF)


Prof. Stephan WindeckerBut why do they do it? CPG Chair, Professor Stephan Windecker (Inselspital, University of Bern, Bern, Switzerland) explains, “For 25 years, ESC Guidelines have been summarising relevant evidence on a given topic to inform physicians on the benefits and risks of particular diagnostic or therapeutic procedures, with the ultimate aim to improve patient care. This year’s new ESC Guidelines cover a range of distinct issues, including some of the most frequent cardiovascular diseases as well as commonly present risk factors. Over the last few years, data from large-scale randomised clinical trials have generated opportunities for novel treatments and technologies to be incorporated into ESC Guidelines, either for the first time or in new ways. For instance, huge outcomes trials have been recently conducted in patients with diabetes to assess cardiovascular safety and in patients with atherosclerotic vascular disease to evaluate novel cholesterol-lowering drugs and strategies. There have also been important advances in the treatment of frequently encountered arrhythmias, supraventricular tachycardias; previous ESC Guidelines on this topic were published in 2003 and therefore it was timely to provide recommendations based on evidence accumulated during the past 15 years. An important new version of the 2014 ESC Guidelines on acute pulmonary embolism will be presented synthesising recent evidence in diagnosis, risk stratification and short- and long-term prevention of recurrent events.”

2013 ESC Guidelines referred to ‘stable coronary artery disease’; however, the nomenclature has been changed to ‘chronic coronary syndromes (CCS)’ in the 2019 update. Task Force Chairs, Professor William Wijns and Professor Juhani Knuuti, state that although coronary artery disease often seems ‘stable’ in between acute events, the underlying disease status is anything but ‘stable’. Prof. Wijns explains, “Atherosclerotic plaque accumulation is a dynamic process that can alter over the continuum of the disease to include growth, stabilisation or regression, as well as changes in plaque composition or thrombosis, depending on lifestyle, risk factor modulation and pharmacological therapies. CCS also better covers the different clinical presentations and multiple syndromes, and, as with heart failure, the new terminology allows clinical presentations to be conveniently categorised as either acute or chronic coronary syndromes, more accurately covering the different stages of the disease.”

2019-guideline-covers-montage.jpgProf. Windecker would like to thank all those who have been involved with the new ESC Guidelines including Task Force representatives, Review Coordinators and the large pool of peer reviewers, including the 57 member National Cardiac Societies. The highly valuable collaborative efforts of the European Atherosclerosis Society (EAS), European Respiratory Society (ERS) and the European Association for the Study of Diabetes (EASD) are also gratefully acknowledged.

Join Prof. Windecker tomorrow for a not-to-be missed overview of all five new 2019 ESC Guidelines. There is also the chance to ‘Meet the Task Force’ for each set of recommendations. And if you want to learn more about the impact of last year’s guidelines, Prof. Windecker and Professor Jean-Philippe Collet will be chairing a ‘2018 ESC Guidelines – One year after’ session this afternoon.

Don’t miss!

2018 ESC Guidelines – One year after
Today, 16:15 – 16:55; ESC TV Stage – ESC Plaza

2019 ESC Guidelines Overview
Sunday, 08:30 – 10:00; Paris – Main Auditorium

Check out the Scientific Programme for all ESC Guidelines sessions >

Access the new 2019 Guidelines >

 

 

Click here to read other scientific highlights in the ESC Congress news.

Download the Saturday Edition in PDF format

Access all the resources from congress presentations on ESC 365.

Follow the congress live!

Notes to editor

About the European Society of Cardiology

The European Society of Cardiology brings together healthcare professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

About ESC Congress 2019

ESC Congress is the world’s largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2019 takes place 31 August to 4 September at the Paris Expo Porte de Versailles, Paris - France. Explore the scientific programme